LKS Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027

Report Description

Global LKS treatment market is anticipated to grow with an impressive CAGR value in the mentioned forecast years 2023-2027 on the account of increasing instances of genetic disorders like LKS syndrome. The increasing demand for the effective treatment for the speech impairment and enhancing memories of the infected children to overcome the growth challenges is further driving the growth of the global LKS treatment market in the upcoming five years.

Landau-Kleffner syndrome (LKS) is a very rare neurological symptomatic disease that is often experienced in children aged 4-7 years. The syndrome is specifically characterized by the gradual or sudden development of aphasia in the children. The patient is unable to understand as their comprehension ability diminishes, along with severe speech impairment or expression toward language.

Patient suffering from LKS often face recurrent seizures like epilepsy, where libs defy the motor functions and actions are abnormal. The instance of LKS is more evident in male patients as compared to females. Mutations in the GRIN2A gene causes the disease which is an autosomal dominant inheritance. Further studies mention other gene mutations that can be responsible for the syndrome among the children.

Increasing Instances Drive Market Growth

Although Landau-Kleffner syndrome is a rare disorder, the instances of the disease are increasing due to various genetic, environmental, and acquiring factors, thus driving the growth of the global LKS treatment market in the upcoming five years. Surge in the demand for the effective treatment and increasing demand for the therapeutic treatment for the disease further supports the growth of the global LKS treatment market in the next five years.

Also, progressing symptomatic treatment for the speech impairment, verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and overt seizures are also substantiating the growth of the global LKS treatment market in the future five years. Increasing demand for the early diagnosis and effective treatment is also aiding the growth of the global LKS treatment market in the forecast years, until 2027.

Advanced Medicine Drives Market Growth

With increasing instances of the LKS and similar diseases like autism, the healthcare sector is driven to find pharmaceutical products, ad therapeutic treatments for the diseases, and thus drive the growth of the global LKS treatment market in the upcoming five years. In 2018, The prevalence rate of autism spectrum disorder among male children in Georgia was 35.2 per 1,000 8-year-olds.

Landau-Kleffner syndrome (LKS) and autism like disease may not claim lives directly but indirectly causes like motor receptor failure, depression, and other related symptoms may cause death among the children as young as 2 to 8 years.

Child Mortality in the first five years of life worldwide in 2019, by region: Africa>Eastern Mediterranean>Southeast Asia>Americas>Western Pacific>Europe. Most cases of child mortality found in African countries are often due to lack of medical attention required for the child suffering from LKS, thus increasing the demand for the treatment in the regions, and also driving the growth of the global LKS treatment market in the region in next five years.

Click here to download the sample

Market Segmentation

The global LKS treatment market segmentation is based on type, treatment, diagnosis, end user, regional distribution, and competitional landscape. Based on type, the market is further bifurcated into focal motor seizures, tonic seizures, and atonic seizures. Treatment based market segmentation is fragmented into anticonvulsant drugs, corticosteroids, intravenous immunoglobulins, surgery, speech therapy, and others.

On the basis of diagnosis, the market is segmented into electroencephalogram (EEG), MRI, audiometry, genetic testing, and others. Based on end user, market is further differentiated into hospitals & clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., Cipla, Inc., Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, are enlisted in a partial list of major market players of the global LKS treatment market.

The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.

Attribute	Details
Base Year	2021
Historical Data	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type Treatment Diagnosis End User
Regional scope	North America; Europe; Asia Pacific; South America; Middle East & Africa
Country scope	United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, South Africa, UAE, Saudi Arabia, Brazil, Argentina, Colombia,
Key companies profiled	Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., Cipla, Inc., Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global LKS treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

LKS Treatment Market, By Type:

Focal Motor Seizures
Tonic Seizures
Atonic Seizures

LKS Treatment Market, By Treatment:

Anticonvulsant Drugs
Corticosteroids
Intravenous Immunoglobulins
Surgery
Speech Therapy
Others

LKS Treatment Market, By Diagnosis:

Electroencephalogram (EEG)
MRI
Audiometry
Genetic Testing
Others

LKS Treatment Market, By End User:

Hospitals & Clinics
Ambulatory Care Centers
Others

LKS Treatment Market, By Region:

North America

United States
Mexico
Canada

Europe

France
Germany
United Kingdom
Italy
Spain

Asia-Pacific

China
India
Japan
South Korea
Australia

Middle East & Africa

South Africa
Saudi Arabia
UAE

South America

Brazil
Argentina
Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global LKS treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global LKS Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global LKS Treatment Market

4. Executive Summary

5. Voice of Customer

5.1. Prevalence, By Geography

5.2. Prevalence, By Gender

5.3. Commonly Observed Symptoms

5.4. Preferred Choice of Treatment

6. Global LKS Treatment Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures)

6.2.2. By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others)

6.2.3. By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others)

6.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

6.2.5. By Company (2021)

6.2.6. By Region

6.3. Product Market Map

7. North America LKS Treatment Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By Treatment

7.2.3. By Diagnosis

7.2.4. By End User

7.2.5. By Country

7.3. North America: Country Analysis

7.3.1. United States LKS Treatment Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By Treatment

7.3.1.2.3. By Diagnosis

7.3.1.2.4. By End User

7.3.2. Mexico LKS Treatment Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By Treatment

7.3.2.2.3. By Diagnosis

7.3.2.2.4. By End User

7.3.3. Canada LKS Treatment Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By Treatment

7.3.3.2.3. By Diagnosis

7.3.3.2.4. By End User

8. Europe LKS Treatment Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type

8.2.2. By Treatment

8.2.3. By Diagnosis

8.2.4. By End User

8.2.5. By Country

8.3. Europe: Country Analysis

8.3.1. France LKS Treatment Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type

8.3.1.2.2. By Treatment

8.3.1.2.3. By Diagnosis

8.3.1.2.4. By End User

8.3.2. Germany LKS Treatment Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type

8.3.2.2.2. By Treatment

8.3.2.2.3. By Diagnosis

8.3.2.2.4. By End User

8.3.3. United Kingdom LKS Treatment Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type

8.3.3.2.2. By Treatment

8.3.3.2.3. By Diagnosis

8.3.3.2.4. By End User

8.3.4. Italy LKS Treatment Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Type

8.3.4.2.2. By Treatment

8.3.4.2.3. By Diagnosis

8.3.4.2.4. By End User

8.3.5. Spain LKS Treatment Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Type

8.3.5.2.2. By Treatment

8.3.5.2.3. By Diagnosis

8.3.5.2.4. By End User

9. Asia-Pacific LKS Treatment Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type

9.2.2. By Treatment

9.2.3. By Diagnosis

9.2.4. By End User

9.2.5. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China LKS Treatment Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type

9.3.1.2.2. By Treatment

9.3.1.2.3. By Diagnosis

9.3.1.2.4. By End User

9.3.2. India LKS Treatment Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type

9.3.2.2.2. By Treatment

9.3.2.2.3. By Diagnosis

9.3.2.2.4. By End User

9.3.3. South Korea LKS Treatment Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type

9.3.3.2.2. By Treatment

9.3.3.2.3. By Diagnosis

9.3.3.2.4. By End User

9.3.4. Japan LKS Treatment Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Type

9.3.4.2.2. By Treatment

9.3.4.2.3. By Diagnosis

9.3.4.2.4. By End User

9.3.5. Australia LKS Treatment Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Type

9.3.5.2.2. By Treatment

9.3.5.2.3. By Diagnosis

9.3.5.2.4. By End User

10. South America LKS Treatment Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type

10.2.2. By Treatment

10.2.3. By Diagnosis

10.2.4. By End User

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil LKS Treatment Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type

10.3.1.2.2. By Treatment

10.3.1.2.3. By Diagnosis

10.3.1.2.4. By End User

10.3.2. Argentina LKS Treatment Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Type

10.3.2.2.2. By Treatment

10.3.2.2.3. By Diagnosis

10.3.2.2.4. By End User

10.3.3. Colombia LKS Treatment Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type

10.3.3.2.2. By Treatment

10.3.3.2.3. By Diagnosis

10.3.3.2.4. By End User

11. Middle East and Africa LKS Treatment Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Type

11.2.2. By Treatment

11.2.3. By Diagnosis

11.2.4. By End User

11.2.5. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa LKS Treatment Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Type

11.3.1.2.2. By Treatment

11.3.1.2.3. By Diagnosis

11.3.1.2.4. By End User

11.3.2. Saudi Arabia LKS Treatment Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Type

11.3.2.2.2. By Treatment

11.3.2.2.3. By Diagnosis

11.3.2.2.4. By End User

11.3.3. UAE LKS Treatment Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Type

11.3.3.2.2. By Treatment

11.3.3.2.3. By Diagnosis

11.3.3.2.4. By End User

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

14.1. Johnson & Johnson

14.2. Novartis AG

14.3. Pfizer, Inc.

14.4. Teva Pharmaceutical Industries Ltd

14.5. Abbott Laboratories, Inc.

14.6. Cipla, Inc.

14.7. Glenmark Pharmaceuticals Limited

14.8. Mankind Pharma Limited

14.9. Novo Nordisk A/S

14.10. Takeda Pharmaceutical Company Limited

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

What are the driving factors of the Global LKS Treatment Market?

Rising awareness about the Landau-Kleffner syndrome along with the concerns for increasing instances of genetic disorders among young children is actively driving the growth of the global LKS treatment market in the upcoming five years.

Which segment of the Global LKS Treatment Market may dominate by end user in the forecast years?

Hospital & Clinics segment is anticipated to dominate the global LKS treatment market by end user segmentation in the forecast years on the account of increasing instances of the disease along with surge in the demand for the efficient treatment for the LKS disease.

Which region may dominate the Global LKS Treatment Market in the future five years?

North America is anticipated to dominate the global LKS treatment market in the future five years due to rapidly increasing medical expenses in the major economies like the United States, Canada, etc.

What are the leading companies of the Global LKS Treatment Market?

Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., are top 5 leading companies that provide effective treatment and therapeutics for the LKS syndrome and support the growth of the global LKS treatment market in the future five years.